54 BIOTECHNOLOGY
Dr Rolf Hansen examines how the latest isolator systems create aseptic working conditions for reducing risk and keeping gene, cell and CAR-T cell therapies effi cient, compliant and accurate
G
ene, cell and CAR-T cell therapies are the latest techniques that use cell manipulation to treat or
prevent diseases such as inherited disorders, some types of cancer and viral infections. In the future, it is likely this progressing fi eld will allow the medical profession to treat a variety of conditions by modifying a patient’s cells instead of using conventional drugs or surgery. Although a promising treatment option for certain diseases, gene therapy is a delicate process and is still being researched to ensure it is safe and eff ective. Bio-contamination found in critical
zones within the gene, cell and CAR-T cell cleanroom environment can put successful patient outcomes at risk, have serious fi nancial consequences and also have a detrimental impact on operational resources. T e critical nature of gene therapy means it is essential to keep cells free from contamination by microorganisms such as bacteria, fungi and viruses. T e risk of microbial contamination is high during the complex cell production procedure, which typically comprises multiple stages, all demanding accuracy and the highest standards of quality control. As a result, regulators are increasingly specifying that Good Manufacturing Practice (GMP) biologics facilities be
www.scientistlive.com
more proactive in providing an aseptic environment with sterile work areas, reagents, media and handling. To ensure GMP compliance for stringent aseptic techniques, cell therapy companies, hospitals and service providers are choosing the latest isolator systems for containing the cell manipulation process. Advanced isolator technology is ideal for the critical nature of gene, cell and CAR-T cell therapy, helping to reduce the risk of contamination by microorganisms or another patient’s cells through product handling and environmental exposure. Off ering space and energy saving
benefi ts, isolators allow cells with limited exposure times to be quickly handled under controlled aseptic conditions.
Innovative workstation T e Bioquell Qube workstation was developed for the aseptic processing and transfer applications widely used in gene, cell and CAR-T cell therapy applications. It is the only modular isolator to off er Bioquell’s built-in Hydrogen Peroxide Vapour technology for rapid decontamination, reduced risk and major cost benefi ts. T e Bioquell Qube far outperforms many traditional isolators for
The Qube workstation from Bioquell
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84
